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 Abstract 26 
 27 
Purpose. Trachoma is a conjunctival scarring disease, which is the leading infectious 28 
cause of blindness worldwide. Elimination of blinding trachoma is being held back by 29 
the high rate of trichiasis recurrence following surgery. There is currently no treatment 30 
available to suppress the pro-fibrotic state and reduce recurrence.  Although the 31 
mechanisms underlying trichiasis development are unknown, the pro-fibrotic phenotype 32 
has been linked to matrix metalloproteinase (MMP) expression. Doxycycline, a well-33 
known tetracycline antibiotic, can act as a broad MMP inhibitor and has showed some 34 
success in preventing fibrosis in various clinical contexts. The purpose of this work was 35 
to assess the anti-scarring properties of doxycycline in an in vitro model of trichiasis 36 
fibroblast-mediated tissue contraction. 37 
Methods. Primary cultures of fibroblasts were established from conjunctival samples 38 
obtained from normal donors or during surgery for trachomatous trichiasis. The effect 39 
of doxycycline on matrix contraction was investigated in our standard collagen gel 40 
contraction model. Cell morphology and matrix integrity were assessed using confocal 41 
reflection microscopy.  Quantitative real time polymerase chain reaction (QRT-PCR) 42 
and a FRET-based assay were used to measure MMP expression and activity 43 
respectively. 44 
Results. Doxycycline treatment successfully suppressed the contractile phenotype of 45 
trichiasis fibroblasts, matrix degradation, and significantly altered the expression of 46 
MMP1, 9 and 12 associated with the pro-fibrotic phenotype.  47 
Conclusions. In view of the results presented here and the wider use of doxycycline in 48 
clinical settings, we propose that doxycycline might be useful as a treatment to prevent 49 
recurrence following trichiasis surgery.  50 
 3 
 51 
Introduction 52 
Trachoma is the leading infectious cause of blindness worldwide 1. The disease 53 
begins with recurrent infection by the bacterium Chlamydia trachomatis in early 54 
childhood, promoting chronic inflammation of the upper tarsal conjunctiva, which leads 55 
to progressive scaring and distortion of the eyelid. The edge of the eyelid turns in 56 
(entropion), so that the lashes scratch the surface of the eye (trichiasis). This can result 57 
in corneal opacity and irreversible sight loss 2. Trachoma is a public health problem in 58 
over 50 countries, predominantly in Sub-Saharan Africa, Middle East, the Indian 59 
Subcontinent, South-east Asia and South America 3. The most recent global estimation 60 
from the World Health Organization (WHO) suggests that 40 million people currently 61 
have active trachoma, a further 8.2 million have trichiasis, and 1.3 million are estimated 62 
to be blind as a result 1. The WHO is leading a Global Alliance to eliminate blinding 63 
trachoma by 2020. This focuses on the implementation of the SAFE Strategy: Surgery 64 
for trichiasis, Antibiotics for infection, Facial cleanliness, and Environmental 65 
improvements to reduce transmission of infection. However, there is growing evidence 66 
that the scarring complications can progress even in the absence of detectable 67 
chlamydial infection 4, and following trichiasis surgery, the anatomical abnormality can 68 
re-develop (from 10% at one year to 60% at three years), in part through an ongoing 69 
immuno-fibrogenic process 5, 6. There is currently no adjuvant treatment available to 70 
suppress the pro-fibrotic state and reduce recurrence.  71 
 72 
The mechanisms underlying post-surgical recurrence of trichiasis are not fully 73 
understood. However, the dysregulated extra cellular matrix (ECM) proteolysis 74 
observed following infection and inflammation is suggested to play a key role in the 75 
 4 
development of fibrotic sequelae 6. MMPs are a tightly regulated family of zinc-76 
dependent enzymes responsible for degrading structural proteins of the ECM, and are 77 
produced by a variety of cell types after injury 7. A number of MMPs have been found 78 
to associate with conjunctival scarring in in vitro models 8, as well as in vivo 9. MMP-9 79 
expression increases when conjunctival inflammation is associated with non-chlamydial 80 
bacterial infection in recurrent trichiasis 10, and an increased level of MMP7 gene 81 
expression was also identified in trichiasis conjunctival samples 11. Moreover, 82 
microarray analysis has confirmed the increased expression of MM7, MMP9 and 83 
MMP12 in conjunctival samples from trichiasis subjects 12. Overall this suggests that 84 
the accumulation of fibrotic tissue in trichiasis might be due at least in part to altered 85 
MMP expression.  86 
 87 
Doxycycline, a well-known tetracycline antibiotic, is widely used to prevent and 88 
treat bacterial and parasite infection, including Chlamydia trachomatis. More recently, 89 
its role as MMP inhibitor and in apoptosis has gathered more attention in the context of 90 
vascular disease 13, 14, pulmonary fibrosis 15, periodontitis 16 as well as ocular pathology 91 
17-19. Doxycycline inhibits MMPs, and particularly MMP9, at sub-antimicrobial doses in 92 
patients 13, 14, 19, 20. In addition, recent work suggests that doxycycline treatment can 93 
dampen local 21, as well as systemic 22, inflammation, thus making it a good candidate 94 
to prevent tissue remodeling and fibrosis in trachoma. Using for the first time 95 
conjunctival cells directly isolated from trachomatous trichiasis-affected individuals, we 96 
demonstrate that doxycycline significantly reduced collagen matrix remodeling and 97 
contraction, and specifically inhibited the mRNA expression of MMP1, 7, 9 and 12 98 
during contraction, suggesting that it could be a potential adjuvant treatment following 99 
trichiasis surgery.  100 
 5 
Material and methods 101 
 102 
Ethics Statement: 103 
This study adhered to the tenets of the Declaration of Helsinki. It was approved by the 104 
Tanzanian National Institute of Medical Research, the Kilimanjaro Christian Medical 105 
Centre, and the London School of Hygiene and Tropical Medicine Ethics Committees. 106 
The study was explained to potential study participants and written informed consent 107 
was obtained before enrolment. 108 
 109 
Clinical Samples: 110 
Conjunctival biopsies were obtained from the upper tarsal conjunctiva from Tanzanian 111 
patients undergoing trichiasis surgery. All cases had tarsal conjunctival scarring with 112 
entropion trichiasis. The eyelid was anaesthetized with an injection of 2% lignocaine 113 
and the eye cleaned with 5% povidone iodine. A biopsy sample was taken using a 3mm 114 
trephine from the tarsal conjunctiva, 2mm from the lid margin, at the junction of the 115 
medial ⅔ and lateral ⅓ of the everted lid. The biopsies were wrapped in sterile gauze, 116 
moistened with normal saline, and transported to the laboratory at +8°C. 117 
 118 
Cell culture and reagents 119 
The biopsies were mechanically dispersed and the tissue fragments were placed in 120 
tissue culture dishes in Dulbecco's modified Eagle's medium (DMEM) with 4.5g/L l-121 
Glutamine (PAA), supplemented with 10% fetal bovine serum (FBS, Sigma), 100 IU/ml 122 
penicillin, 100 ug/ml streptomycin (Invitrogen) at 37 °C with 5% CO2. Following 123 
growth from the explant, the fibroblast populations (F07, F09, F10 and F11) were 124 
trypsinized and maintained routinely in the above medium. All four cell lines were 125 
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tested for C. trachomatis infection using the Amplicor CT/NG Kit (Roche Molecular 126 
Systems, Branchburg, NJ) and were found to be negative. The cells were used between 127 
passage 4 and 9 for all experiments. For doxycyline treatment, a stock solution of 48.7 128 
mM Doxycycline hyclate (Sigma) was made in sterile ultrapure water (Millipore 129 
Biocel) and added to the cell culture medium at final concentrations of 104 and 416 uM.  130 
 131 
Collagen contraction assay 132 
The collagen contraction assays were performed as previously described 8. Trachoma 133 
cells were seeded in a 1.5 mg/ml collagen type-I matrix (First Link Ltd) at a 134 
concentration of 7x104 cells/ml. The gels were detached from the edge of the well, and 135 
2 mL of DMEM with/without Doxycycline was added. Gel contraction was monitored 136 
daily for 7 days by digital photography. Gel areas were measured using ImageJ software 137 
(http://rsb.info.nih.gov/ij/), and the contraction was plotted as a percentage of gel area 138 
normalized to original area (day 0 measurement).  139 
 140 
Cytotoxicity assay 141 
Cytotoxicity was determined using a Cytotoxicity Detection Kit (LDH) (Roche), on 142 
media collected at the termination of the gel contraction experiment (in phenol red-free 143 
DMEM) to measure the percentage of lactate dehydrogenase activity present in the 144 
samples. The gels were  lysed in 2% Triton X-100 (Sigma) in phenol red free, serum 145 
free DMEM for 10min to achieve the maximum LDH release. Absorbances were 146 
measured at 490 nm (Fluostar Optima) and the percentage of cytotoxicity was 147 
calculated according to the manufacturer's protocol.  148 
  149 
 150 
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Cell and matrix imaging 151 
Following contraction for 7 days with/without 416uM doxycycline, gels were fixed in 152 
3.7% paraformaldehyde (Sigma) at room temperature for 30 min, followed by 153 
permeabilization with 0.5% Triton X-100 (Sigma) for 30 min, and staining with 154 
rhodamine-phalloidin (Invitrogen) for 1hr 8, 23. Imaging was carried out on a Zeiss 155 
Axiovert S100/Biorad Radiance 2000 confocal laser scanning microscope using 156 
simultaneous reflection microscopy and fluorescence imaging 23. Representative images 157 
were acquired as z-stacks using a long working distance objective (Zeiss 63X/0.75 plan 158 
neo fluar with correction collar).  The resulting volumes were imported into Image J 159 
where the fluorescence channel (F-actin staining) was compressed to a single projection 160 
and merged with a representative section of the matrix.  161 
 162 
Quantitative Real-Time PCR 163 
Collagen gel contraction assays were ended at days 0, 3, and 7 by placing the gels 164 
straight into TRIzol Reagent (Invitrogen) at 4 °C for 1hr. Control mRNA at day 0 were 165 
obtained after 1hr of initial gel polymerization. Homogenization and phase separation 166 
were carried out according to the TRIzol manufacturer’s instructions. The aqueous 167 
phase was harvested and used for RNA isolation using the RNeasy Mini Kit according 168 
to the standard protocol (Qiagen). Reverse transcription was carried out using the 169 
QuantiTect Reverse Transcription Kit (Qiagen) according to manufacturer’s instructions. 170 
MMP gene expression was measured by QRT-PCR using validated primers and probes 171 
(Assay-on-Demand; Applied Biosystems). Assay identification numbers are MMP1 172 
(Hs00899658_m1), MMP2 (Hs01548727_m1), MMP7 (Hs01042796_m1), MMP9 173 
(Hs00234579_m1), and MMP12 (Hs00899662_m1). The HPRT1 gene was used as an 174 
endogenous control to normalize sample concentration. RT-PCR reactions were 175 
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performed on an HT7900 Fast Real-Time PCR system (Applied Biosystems), and the 176 
2(-Delta Delta C(T)) Method (Livak and Schmittgen, 2001) was used for quantification 177 
of mRNA levels. 178 
 179 
MMP activity assay 180 
Total MMP activity was determined using a FRET-based MMP activity assay kit 181 
according to the manufacturer’s protocol (Abcam, ab112147). In brief, 25ul of medium 182 
from control and doxycycline-treated collagen gel contraction cultures at day 0, 3 and 7 183 
were added to 25ul of 2mM APMA solution and incubated at 37°C for 3hrs. 50ul of the 184 
MMP Red Substrate was then added and the mix was incubated at room temperature for 185 
1hr. Fluorescence was measured at Ex/Em=540/590nM (Fluostar Optima).  186 
 187 
Statistical analysis 188 
All graphs display mean and standard error. Statistical analysis was performed using the 189 
Students t test to establish significant differences and individual P values displayed. 190 
  191 
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Results 192 
 193 
Doxycycline prevents collagen matrix remodeling and contraction by trichiasis 194 
fibroblasts 195 
We used our well-characterized in vitro model of cell-mediated matrix 196 
contraction 8, 23-26 to assess the contractile potential of primary fibroblasts isolated from 197 
the conjunctiva of patients with trachomatous trichiasis and evaluate the potential of 198 
doxycycline as a modulator of contraction. As expected from their conjunctival and 199 
fibrotic origin 23, 25, trichiasis fibroblasts (F07, F09, F10 and F11) contracted collagen 200 
matrices strongly, down to 20-30% of their original size over 7 days in the presence of 201 
10% serum. The application of 104uM of doxycycline for 7 days was sufficient to 202 
reduce matrix contraction by 25% and more significantly, a 7-day treatment with 203 
416uM of doxycycline prevented the contraction by up to 75% (Fig. 1 A). Figures 1B 204 
and 1C show 2 representative contraction kinetics from F10 and F11 fibroblast lines, 205 
illustrating that doxycycline treatment reduced gel contraction as early as at day 1, with 206 
the effect of the drug increasing with incubation time for the higher concentration. To 207 
confirm that this effect was not due to drug toxicity, a lactate dehydrogenase (LDH) 208 
assay was performed on the cells within collagen gels following 7-day doxycycline 209 
treatment at 104 or 416uM. We found no detectable toxicity effect for the drug at either 210 
concentration (Fig. 1D).  211 
We have shown previously that fibroblast-mediated gel contraction is dependent 212 
on the ability of the cells to affect the organization of pericellular collagen fibers 213 
through both direct mechanical pulling on the fibers to align and compact them, as well 214 
as by matrix degradation through the release of MMPs 23, 24. To determine how 215 
doxycycline prevented gel contraction, we used confocal microscopy to assess cell 216 
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morphology and pericellular matrix organization in the gels following doxycycline 217 
treatment. As all 4 cell lines behaved identically in terms of matrix contraction and 218 
response to doxycycline (data not shown), we selected 2 representative cell lines, F10 219 
and F11, to perform these studies and further work.  Trichiasis-derived fibroblasts had a 220 
stellate appearance in the gels, with long F-actin rich protrusions, as illustrated by the 221 
full projection of the cell volume23 (Fig.2, red staining). In agreement with the toxicity 222 
data, the overall morphology of the cells appeared unaltered by the doxycycline 223 
treatment. Consistent with our previous work on other types of fibroblasts, the high 224 
contractile profile of the trichiasis fibroblasts was linked to extensive remodeling and 225 
degradation of the collagen matrix by day 7, as visualized by a lack of distinct collagen 226 
fibers following confocal reflection imaging8, 23. Areas of dense compacted poorly 227 
resolved collagen clumps could be seen as a bright white aura around the cells (Fig. 2, 228 
arrows), whilst the rest of the matrix shows a fuzzy appearance, characteristic of MMP-229 
mediated degradation 23. By contrast, in presence of 416uM doxycycline, the matrix 230 
fibers remained clearly defined and evidence of fiber alignment consecutive to active 231 
cell pulling on the matrix can be found surrounding most of the cells (Fig. 2, 232 
arrowhead).  233 
 234 
Doxycycline reduces MMP expression during collagen matrix contraction  235 
Our morphological analysis of the cells and matrix during contraction strongly 236 
suggested that doxycycline could act through a modulation of matrix degradation and 237 
thus likely MMP release. MMPs have long been connected to scarring processes. We 238 
have previously shown that matrix remodeling by MMPs plays an important role in 239 
tissue contraction, both in in vitro 8, 23, ex vivo 8, as well as in an ocular scarring model 240 
in the rabbit model of glaucoma filtration surgery 27. In addition, our recent studies have 241 
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suggested a role for MMPs in the development of the fibrotic phenotype in trachoma 10, 242 
11. We thus used real-time PCR to evaluate MMP expression during matrix contraction. 243 
We chose to investigate levels of MMP1 as a well known collagenase previously 244 
implicated in our standard collagen contraction assay 26, MMP2 as a standard gelatinase, 245 
and MMP7, MMP9 and MMP12 as these particular MMPs have been found enriched in 246 
trichiasis samples 12. The CT values from the RT-PCR study demonstrated that all of 247 
above MMPs were present in both F10 and F11 at Day 0. MMP1 and 2 were expressed 248 
at significant levels, whilst MMP7 and 9 were naturally low (Table 1). All MMPs 249 
showed an increased expression during contraction in the control group, although to 250 
different extent and kinetics. While MMP1, MMP2 and MMP12 showed a sustained 251 
increase throughout the contraction kinetics, MMP9 expression peaked at day 3 (Fig. 3). 252 
Continuous treatment with 416uM doxycycline did not significantly affect MMP2 253 
expression (Fig. 3C, D). However, MMP1 (Fig. 3 A, B), MMP9 (Fig. 3 E, F) and 254 
MMP12 (Fig. 3 G, H) all show a strong reduction in expression in the presence of the 255 
drug.  We also observed a similar trend for MMP7 in F10 (Table 1, normalized 256 
expression data not shown), but could not confirm this effect in F11 due to its lower 257 
expression of MMP7 and the technical limitation of RT-PCR. To confirm that the effect 258 
of doxycycline on MMP gene expression led to a reduction in protein expression and 259 
activity, we measured the total MMP activity released in the medium during contraction. 260 
As expected, the total MMP activity releasable from the medium increased significantly 261 
during contraction, particularly in F10, matching the gene expression profile (Fig. 4). 262 
Treatment with doxycycline completely abrogated MMP activity, even in medium at 263 
day 0, suggesting that doxycycline affected both the MMP protein levels and the 264 
activity of the MMPs present in the medium.  265 
 266 
 267 
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Discussion 268 
 269 
Using our in vitro model of cell-mediated matrix contraction 8, 23-26, we found 270 
that doxycycline significantly reduced the contractile potential of primary fibroblasts 271 
isolated from the conjunctiva of patients with trachomatous trichiasis, whilst presenting 272 
only minimal toxicity. This low toxicity and strong effect on contraction compares 273 
favorably with previously studied inhibitors of matrix contraction targeting cell division 274 
28, matrix metalloproteinase activity 8, 23, 29 or small Rho GTPases 26, which have been 275 
found to prevent tissue contraction ex-vivo 26, 29, and scarring in vivo, both in animal 276 
models  27 and in the clinic 30, 31. Our results suggest that doxycycline’s effect on 277 
contraction is at least partly mediated by its ability to inhibit MMP expression and 278 
activity, which we have shown is a major component of the contraction process 8, 23, 26. 279 
In addition, doxycycline appears to selectively target the expression of MMP1, 7, 9 and 280 
12, which have been linked to the fibrotic phenotype in trachoma. Doxycycline has 281 
previously been shown to both reduce MMPs expression levels 32, 33, and affect MMP 282 
activity 13, 19, 33. In particular, it reduced MMP2 and MMP9 activity during gel 283 
contraction in vitro 34 and fibrosis in vivo 35, suggesting that doxycycline’s effects on 284 
MMP underlies at least part of its strong effect on matrix remodeling in trachoma. 285 
Whilst the doxycycline inhibition of MMP activity is known to involve zinc chelation, 286 
the mechanism by which doxycycline affects MMP gene expression is still unclear. 287 
However, as doxycycline appears to broadly affect the pro-inflammatory response, it 288 
could affect MMP expression through a downregulation of MMP-inducing pro-289 
inflammatory cytokines21, 22, 32. 290 
MMP1, one of the main collagenases, has been linked to pathological processes 291 
such as fibrotic diseases and cancer 36. Although it has not been reported in association 292 
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with trichiasis, our previous work with human Tenons’ capsule fibroblasts has shown 293 
that it is heavily expressed during matrix contraction in vitro and its reduction is linked 294 
to a decrease in contraction 26, suggesting that it may also functionally facilitate the 295 
matrix remodeling process during trichiasis. MMP7 is expressed in epithelia and injured 296 
tissue. It plays an important role in inflammation 37, 38. MMP7 upregulation not only 297 
participates in ECM regulation, but also correlates with many fibrotic diseases 39, 298 
including trachoma 11 and tumor metastasis 40. MMP9 is a major component of ECM 299 
turnover during homeostasis and conjunctival scarring 41, and its expression is closely 300 
linked to the degree of inflammation in the human conjunctival epithelium of children 301 
with active trachoma 42, 43. We found here that trichiasis-derived fibroblasts express low 302 
levels of MMP7 and 9. However, both MMP levels are increased transiently during the 303 
contraction process, suggesting that these MMPs may be functional and activated 304 
mostly at the initial stage. The extremely low expression of MMP7 in F11 might be the 305 
result of the natural biological variation of F11, together with the technical limit of 306 
semi-quantitative RT-PCR. MMP12 on the other hand is mainly produced by 307 
macrophages, its main function including degrading elastin and taking part in pro-308 
inflammatory processes 44. Increased MMP12 expression has been reported in the 309 
scarred conjunctiva of people with trichiasis either with or without inflammation 12. Our 310 
results showed MMP12 has a modest but consistent increasing during the matrix 311 
contraction both in F10 and F11, suggesting that it could directly contribute to matrix 312 
remodeling in trichiasis. Interestingly, though doxycycline treatment was shown to 313 
significantly inhibit MMP12 expression in both cell lines studied, it was significantly 314 
more efficient in preventing the contraction of F11, which did not express significant 315 
levels of MMP7 and MMP9. This suggests that in the absence of MMP7 and MMP9, 316 
MMP12 might be a significant factor driving trichiasis fibroblast-mediated contraction. 317 
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 318 
Doxycycline’s potential as a MMP inhibitor has been extensively documented 319 
and it has proved useful in clinical settings 14, 20, with many reporting its strong effect on 320 
MMP9 13, 14, 19. Recent work suggests that it can also modulate inflammation 21, 22, thus 321 
making it a good candidate to prevent the immunofibrogenic process that underlies 322 
recurrent trachomatous trichiasis. We present here evidence that doxycycline prevents 323 
matrix remodeling and contraction by trichiasis-derived fibroblasts and leads to a 324 
significant down-regulation in MMP expression in these cells. The in vitro model of 325 
tissue contraction used here has already proved essential to the development of 326 
treatments for the prevention of scarring following glaucoma filtration surgery and a 327 
reasonable predictor of the clinical potential of anti-scarring treatments 30. In the 328 
absence of any animal model for trichiasis development and recurrence, this in vitro 329 
model may facilitate the translational pathway to modeling the pathogenesis of 330 
trachoma and evaluating the effectiveness of new treatments in advance of clinical trials. 331 
In view of our results and the wider use of doxycycline in clinical settings, we propose 332 
that doxycycline might be useful as a treatment to prevent recurrence following 333 
trichiasis surgery.  334 
 335 
 336 
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 485 
Table1: Quantitative RT-PCR CT values for MMP mRNA expression levels during 486 
gel contraction.  CT values are averaged from n≥3 experiments.  487 
488 
Gene$
$
MMP1$
$
MMP2$
$
MMP7$
$
MMP9$
$
MMP12$
$
$
HPRT1$
$
Dox$
$
1$
$
+$
$
1$
$
+$
$
1$
$
+$
$
1$
$
+$
$
1$
$
+$
$
1$
$
+$
$
F10$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$
Day$0$ 31.1$±$0.4$ 29.1$±$2.1$ 25.1$±$0.5$ 24.5$±$0.6$ 39.6$±$0.3$ 38.2$±$0.9$ 39.0$±$0.3$ 37.5$±$1.0$ 34.8$±$0.8$ 34.1$±$0.8$ 29.8$±$0.8$ 29.8$±$0.8$
Day$3$ 23.3$±$0.7$ 24.0$±$0.5$ 23.4$±$0.4$ 22.8$±$0.2$ 35.9$±$0.4$ 36.7$±$0.7$ 33.9$±$0.5$ 34.0$±$0.7$ 31.7$±$0.8$ 32.9$±$0.7$ 30.9$±$0.8$ 30.4$±$0.5$
Day$7$ 23.0$±$0.4$ 25.9$±$0.7$ 22.1$±$0.2$ 22.2$±$1.2$ 36.3$±$0.2$ 37.2$±$1.0$ 34.6$±$0.5$ 35.5$±$0.9$ 30.3$±$0.8$ 32.7$±$0.9$ 30.0$±$0.7$ 30.1$±$1.0$
F11$
Day$0$ 30.4$±$0.4$ 29.4$±$0.1$ 26.5$±$2.3$ 27.7$±$3.4$ 37.0$±$0.1$ n/a$ 40.4$±$0.9$ 37.0$±$2.6$ 34.4$±$1.3$ 34.4$±$1.0$ 31.9$±$0.9$ 32.1$±$0.8$
Day$3$ 26.3$±$0.2$ 27.0$±$0.5$ 23.5$±$0.2$ 21.9$±$0.9$ 41.3$±$1.4$ 39.2$±$0.6$ 39.0$±$0.2$ 39.7$±$0.5$ 34.1$±$1.7$ 37.0$±$0.4$ 32.0$±$0.4$ 30.3$±$1.2$
Day$7$ 25.6$±$0.5$ 27.6$±$0.7$ 23.2$±$0.2$ 22.4$±$1.3$ 40.8$±$0.9$ 40.5$±$0.7$ 39.9$±$0.6$ 41.1$±$1.3$ 33.6$±$1.4$ 38.5$±$0.6$ 32.0$±$0.6$ 30.6$±$1.6$
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Figure legends:  489 
 490 
Figure 1: Doxycycline treatment prevents collagen matrix contraction by trichiasis 491 
fibroblasts. (A) Effect of Doxycycline on trichiasis fibroblasts (pooled data for F07, F09, 492 
F10 and F11) gel contraction at day7. Each data point was averaged from triplicate gels, 493 
n=3. *p<0.05, **p<0.01, ***p<0.001. (B, C) Representative collagen gel contraction 494 
profile for F10 and F11 (mean ± SEM, 3 gels each). (D) Cytotoxicity as measured by 495 
LDH activity release into the medium during contraction after 7-day. The data is shown 496 
as percentage cell survival (mean ± SEM, for n=3 gels each). 497 
 498 
Figure 2: Doxycycline treatment prevents matrix degradation and remodeling. 499 
Trichiasis fibroblasts F10 and F11 were embedded in collagen gels in medium 500 
with/without 416 uM doxycycline. The gels were fixed and stained with Rhodamine 501 
phalloidin after 7 days. Shown are representative images of cells embedded in the 502 
matrix: red,  2D projection of the full cell F-actin volume; white, collagen matrix fibers 503 
viewed using confocal reflection microscopy. Arrows show pericellular collagen fibers 504 
compaction, arrowhead radial alignment consecutive to cell dynamic activity.  Scale bar, 505 
10 um. 506 
 507 
Figure 3: Doxycycline inhibits MMP expression during contraction. Quantitative RT-508 
RCR for MMP1 (A, B), MMP2 (C, D), MMP9 (E, F) and MMP12 (G, H) mRNA 509 
expression in trichiasis fibroblasts F10 and F11 during contraction with/without 416 uM 510 
doxycycline. Significant differences in expression during contraction with reference to 511 
the value at day 0 are expressed as *p<0.05, **p<0.01, ***p<0.001; significant 512 
 24 
differences between control and treated samples on the same day are expressed as 513 
+p<0.05, ++p<0.01, +++p<0.001 (mean ± SEM, n=3 repeats).   514 
 515 
Figure 4: Doxycycline inhibits MMP activity during contraction. The total MMP 516 
activity released in the medium by F10 and F11 cells with/without doxycycline 517 
treatment was measured at day 0, 3 and 7 during contraction using a FRET based assay. 518 
MMP activity is expressed as fluorescence levels (mean ± SEM; F10, n=3; F11 n=2).   519 
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